1. Home
  2. RLYB vs CING Comparison

RLYB vs CING Comparison

Compare RLYB & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rallybio Corporation

RLYB

Rallybio Corporation

HOLD

Current Price

$0.68

Market Cap

24.1M

Sector

Health Care

ML Signal

HOLD

CING

Cingulate Inc.

HOLD

Current Price

$3.92

Market Cap

27.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RLYB
CING
Founded
2018
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.1M
27.0M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
RLYB
CING
Price
$0.68
$3.92
Analyst Decision
Hold
Strong Buy
Analyst Count
2
3
Target Price
N/A
$31.33
AVG Volume (30 Days)
168.3K
130.3K
Earning Date
11-06-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$674,000.00
N/A
Revenue This Year
$17.61
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
12.71
N/A
52 Week Low
$0.22
$3.20
52 Week High
$1.24
$6.01

Technical Indicators

Market Signals
Indicator
RLYB
CING
Relative Strength Index (RSI) 59.52 55.60
Support Level $0.65 $3.80
Resistance Level $0.68 $4.02
Average True Range (ATR) 0.04 0.18
MACD 0.00 0.06
Stochastic Oscillator 97.40 82.35

Price Performance

Historical Comparison
RLYB
CING

About RLYB Rallybio Corporation

Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.

About CING Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.

Share on Social Networks: